Peptide Therapeutics Forum 2019 (Basel Life)

Peptide Therapeutics Forum 2019 (Basel Life)

The forum will highlight important new insights regarding the drug discovery of peptides including examples for successful development. The first day is dedicated to topics to be addressed more early during peptide optimization, and the second day more on issues related to later-stage development. 

Start Date 11.09.2019 - 10:00
Event End 12.09.2019 - 16:30
Location Congress Center Basel
Website

The framework of the BASEL LIFE, we will host the “Peptide therapeutics forum 2019” for 2 days on September 10, and 11. Similar to previous events, presentations highlight important new insights regarding the drug discovery of peptides including examples for successful development. The first day is dedicated to topics to be addressed more early during peptide optimization, and the second day focuses more on issues related to later-stage development. As in the past, this event is thought to disseminate information on latest news in the broad field of therapeutic peptides and to enable networking of interested parties from academia and industries.

Confirmed Speakers:

  • Dr. Frank Otto Gombert (GPRS - Gombert Pharma Research Solutions, Basel, CH), «New Trends in Clinical Development of Peptide Therapeutics»
  • Michael Koehler (Genentech Research & Early Development, San Francisco, United States),«Optimization of the lipopeptide arylomycin natural product into Gram-negative antibiotics»
  • Helene Adihou (Astra Zeneca, Dortmund, Germany), «Activation of the Hippo pathway via targeting of transcription factor TEAD using designed tertiary protein structure mimetics»
  • Dieter Willbold (University of Düsseldorf, Germany), «Elimination of Aβ oligomers by the orally available all-D-peptide PRI-002 reverses cognition deficits and decelerates neurodegeneration»
  • Richard DiMarchi (University of Indiana, Bloomington, United States), «The chemical evolution of endocrine hormones»
  • David Perrin (University of British Columbia, Vancouver, Canada), «Peptide platforms for therapy and imaging: The first total synthesis of amanitin for ADCs and one-step 18F-labeling PET-oncology»
  • Michael Ruff (Creative BioPeptides, Rockville, Maryland), «Orally active short chemokine antagonist peptides for pain, stroke, and neurodegeneration»
  • Andrew Kennedy (Gyros Protein Technologies, Uppsala, Sweden), «Strategies for efficient, optimized high throughput solid phase peptide synthesis of challenging peptides»
  • Anna Maria Papini (University of Florence, Italy), «Exotic side chain-to-side-chain cyclization modes in octreotide analogs for tumor pretargeting»
  • Melpomeni Fani (University Hospital Basel, Switzerland), «Peptide-based radiopharmaceuticals for cancer imaging and therapy
    Agonist or Antagonist? Does it really matter?»
  • Walter Mier (University of Heidelberg, Germany), «Vancomycin regains effectiveness for resistant bacteria by conjugation to cationic peptides »
  • Mark Smythe (Protagonist, Newark, United States), «Peptide discovery at protagonist therapeutics: A platform yielding multiple clinical candidates»
  • Mike Pennington (AmbioPharm, North Augusta, United States), «Disulfide-rich peptide production»
  • Jon Collins (CEM, Matthews, United States), «A new green solvent for solid phase peptide synthesis»
  • Christian Becker (University of Vienna, Austria), «Synthetic immune system engagers target cancer cells and prevent tumor formation»
  • Roxana Drake & Marc Thommen (Santhera Pharmaceuticals CH Ltd., Pratteln, Switzerland), «Discovery and clinical development of an inhaled cyclic peptide elastase inhibitor for the treatment of cystic fibrosis»
  • John Offer (The Francis Crick Institute, London, United Kingdom), «Peptide solubility and synthesis»

Contact:

Chairs:

Thomas Vorherr (Novartis, Basel, Switzerland)
Roderich Süssmuth (Technical University Berlin, Germany)